癌症研究
激酶
后天抵抗
酪氨酸激酶
药理学
克里唑蒂尼
小分子
药品
药物开发
间变性淋巴瘤激酶
肿瘤科
表皮生长因子受体
药物发现
埃罗替尼
阿列克替尼
作者
Jonas Lategahn,Marina Keul,Daniel Rauh
标识
DOI:10.1002/anie.201710398
摘要
The treatment of non-small cell lung cancer (NSCLC) is currently experiencing a revolution. Over the last decade, the knowledge gained about the biochemical features of biomarkers and their predictive abilities has led to the development of targeted small-molecule inhibitors that present an alternative to harsh chemotherapy. The use of these new therapies has improved the quality of life and increased the survival of patients. The occurrence of inevitable drug resistance requires the constant development of precision medicine. The detailed understanding of the target biology and the search for innovative chemical approaches has encouraged investigations in this field. Herein, we review selected aspects of the molecular targets and present an overview of current topics and challenges in the rational development of small molecules to target NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI